Projected Price to Earnings: Qilian International Holding Group (QLI)

Graphic logo of Qilian International Corp (QLI)

Demand for Chinese pharmaceutical raw materials remains stable, minimizing business cyclicality for Qilian International (QLI). The issuer's forward P/E demonstrates a correlation between share prices and expected earnings, with 0.00 representing the current metric. Regulatory reforms and pressure from the public sector are compressing sales margins; however, owning plants in agricultural zones guarantees a steady distribution of chemical components to farmers.

QLI - qlsyy.net Future Price to Earnings Multiple over the range 07/04/2022 - 08/17/2024

Financial and market metric breakdowns for qlsyy.net (QLI)

- stock value and consensus price forecast:
Initial company analysis:Qilian International Corp
Signature product of Qilian International

For Qilian International (QLI), which relies on stable demand within the traditional medicine sector, the company's expected P/E multiple reflects the market valuation of future cash flows. This indicator is calculated as the ratio of the current share price to the projected earnings per share, allowing investors to assess the premium paid for the asset given the issuer's sustainable operating margin and robust FCF.

Main competitors

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple Eupraxia Pharma (EPRX)|Future Price to Earnings BioHarvest Sciences Inc. BHST|EXOZ - Projected Price to Earnings|ORMP: Projected Price to Earnings|Future Price to Earnings Multiple ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio abvcpharma.com (ABVC)|Future Price to Earnings Cumberland Pharma|Future Price to Earnings QNTM|Forward P/E Multiple FGEN|TELO (Telomir Pharma) - Future Price to Earnings Multiple|Future Price to Earnings Rani Therapeutics Holdings RANI|SNYR - Projected Price to Earnings|RLYB - Future Price to Earnings|Market Cap to Projected Earnings lexariabioscience.com LEXX|PULM: Forward P/E Multiple|Price to Future Earnings Ratio PTHL|Future Price to Earnings Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Forward P/E Multiple IBO|Market Cap to Projected Earnings TNF Pharmaceuticals, Inc.|Forward P/E Multiple YCBD (cbdMD, Inc.)|PRFX (PainReform Corp) - Price to Expected Earnings Ratio|CYTO: Projected Price to Earnings|LIPO - Forward P/E Multiple|OptiNose, Inc. (OPTN) - Future Price to Earnings|PIRS - Market Cap to Projected Earnings|Future Price to Earnings Procaps|Projected Price to Earnings Petros (PTPI)|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP